Agilent Technologies

Lawrence (Larry) Lesko is a bioanalytical veteran with many years of academic and FDA experience. Now, as director of the University of Florida’s Center for Pharmacometrics and Systems Pharmacology, Larry uses metabolomics to discover biomarkers of drug toxicity.

As associate scientific director of Nutritional Chemistry and Food Safety at Covance Laboratories, Katerina Mastovska must tackle the most challenging analytical questions. And she loves every second.

Let’s go back to the early 1990s when an important innovation was starting to cause a stir. Electrospray ionization (ESI) essentially allowed liquid chromatography (LC) and mass spectrometry (MS) to be combined much more easily as an analytical technique.

In early 2014, Agilent Technologies approached us with a clear objective: to show how simple and robust two-dimensional liquid chromatography has become.

Ole Gron has been in the pharmaceutical industry for over 10 years after finding his way into separation science via spectroscopy.

Concluding our series on two-dimensional liquid chromatography, we talk with a pair of relative newcomers who relate their experiences to date and discuss how they plan to take advantage of the technique in the future.

Over 10 years ago, the potential of two-dimensional liquid chromatography seemed obvious to me – so I built a system and never looked back.

Impurity analysis with simultaneous determination of enantiomeric composition using the Agilent 1290 Infinity 2D-LC Solution

In recent years, the top ten pharmaceuticals sales list has been extensively populated with protein therapeutics, such as monoclonal antibodies and recombinant proteins, that are used to treat various life-threatening diseases, including cancer and autoimmune diseases.

Two-dimensional liquid chromatography certainly sounds impressive and produces some pretty pictures, but is it essential in the analysis of complex samples? Here, we show that 2D-LC offers both style and substance.